PR Newswire
MARLBOROUGH, Mass., Oct. 26, 2023
MARLBOROUGH, Mass., Oct. 26, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.527 billion during the third quarter of 2023, growing 11.2 percent on a reported basis, 11.1 percent on an operational1 basis and 10.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $505 million or $0.34 per share (EPS), compared to $174 million or $0.12 per share a year ago, and achieved adjusted3 EPS of $0.50 for the period, compared to $0.43 a year ago.
"We achieved another quarter of strong performance, thanks to the hard work of our talented global team and our differentiated medical technologies that improve the lives of patients across the globe," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "As we shared at our recent Investor Day meeting, we are well-positioned for the long term, backed by our category leadership strategy, strong pipeline of innovation and track record of strong commercial execution."
Third quarter financial results and recent developments:
1. Operational net sales growth excludes the impact of foreign currency fluctuations. |
2. Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales. |
3. Adjusted EPS excludes the impacts of certain charges (credits) which may include amortization expense, goodwill and intangible asset impairment charges, acquisition/divestiture-related net charges (credits), investment portfolio gains and losses, restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits), EU MDR implementation costs, debt extinguishment charges, deferred tax expenses (benefits) and discrete tax items. |
4. Periodically, we assess our list of Emerging Markets countries, and effective January 1, 2023, modified our list to include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada. We have revised prior year amounts to conform to the current year's presentation. |
5. The FARAPULSE PFA System and the AGENT DCB are investigational devices. Restricted by Federal law to investigational use only. Not available for sale in the U.S. |
Net sales for the third quarter by business and region:
| | | | | Increase/(Decrease) | ||||||||
| | Three Months Ended | | Reported | | Impact of | | Operational | | Impact of | | Organic | |
(in millions) | 2023 | 2022 | | | | | | ||||||
| Endoscopy | $ 629 | $ 559 | | 12.6 % | | (0.7) % | | 11.9 % | | (1.4) % | | 10.6 % |
| Urology | 483 | 433 | | 11.5 % | | (0.5) % | | 11.1 % | | — % | | 11.1 % |
| Neuromodulation | 229 | 221 | | 3.7 % | | (0.4) % | | 3.2 % | | — % | | 3.2 % |
| MedSurg | 1,341 | 1,213 | | 10.6 % | | (0.5) % | | 10.0 % | | (0.6) % | | 9.4 % |
| Cardiology | 1,647 | 1,479 | | 11.4 % | | (0.1) % | | 11.4 % | | — % | | 11.4 % |
| Peripheral Interventions | 538 | 479 | | 12.3 % | | 0.6 % | | 12.9 % | | (4.5) % | | 8.4 % |
| Cardiovascular | 2,185 | 1,958 | | 11.6 % | | 0.1 % | | 11.7 % | | (1.1) % | | 10.6 % |
Net Sales | $ 3,527 | $ 3,170 | | 11.2 % | | (0.1) % | | 11.1 % | | (0.9) % | | 10.2 % | |
| | | | | | | | | | | | | |
| | | | | Increase/(Decrease) | | | | | ||||
| | Three Months Ended | | Reported | | Impact of | | Operational | | | | | |
(in millions) | 2023 | 2022 | | | | ||||||||
| U.S. | $ 2,099 | $ 1,934 | | 8.5 % | | — % | | 8.5 % Werbung Mehr Nachrichten zur Boston Scientific Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE (Mit der Bestellung akzeptierst du die Datenschutzhinweise) -1 Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink. Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte. Andere Nutzer interessierten sich auch für folgende News |